Ventyx Biosciences, Inc.

NasdaqGS:VTYX Stock Report

Market Cap: US$558.0m

Ventyx Biosciences Management

Management criteria checks 3/4

Ventyx Biosciences' CEO is Raju Mohan, appointed in Nov 2018, has a tenure of 7.17 years. total yearly compensation is $1.28M, comprised of 48.5% salary and 51.5% bonuses, including company stock and options. directly owns 3.33% of the company’s shares, worth $18.56M. The average tenure of the management team and the board of directors is 1.4 years and 4 years respectively.

Key information

Raju Mohan

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage48.47%
CEO tenure7.2yrs
CEO ownership3.3%
Management average tenure1.4yrs
Board average tenure4yrs

Recent management updates

Recent updates

Ventyx Biosciences: Why Caution Should Remain

Nov 11

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

Sep 23
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

May 05
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully

Nov 14
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Nov 04

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Jul 12
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)

Jul 01

Ventyx Pivots To Obesity Amid Transformation

Mar 12

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Feb 15
Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Ventyx: Too Risky Right Now After Some Poor Data

Jan 18

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

Sep 21
Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Feb 20
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Ventyx Biosciences: Not Chasing This Rally

Sep 18

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Aug 19
We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06

Aug 15

CEO Compensation Analysis

How has Raju Mohan's remuneration changed compared to Ventyx Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$107m

Jun 30 2025n/an/a

-US$119m

Mar 31 2025n/an/a

-US$124m

Dec 31 2024US$1mUS$622k

-US$135m

Sep 30 2024n/an/a

-US$153m

Jun 30 2024n/an/a

-US$171m

Mar 31 2024n/an/a

-US$193m

Dec 31 2023US$9mUS$596k

-US$193m

Sep 30 2023n/an/a

-US$181m

Jun 30 2023n/an/a

-US$158m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$4mUS$567k

-US$108m

Sep 30 2022n/an/a

-US$91m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$15mUS$423k

-US$85m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$79m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$68kUS$37k

-US$28m

Compensation vs Market: Raju's total compensation ($USD1.28M) is below average for companies of similar size in the US market ($USD2.29M).

Compensation vs Earnings: Raju's compensation has been consistent with company performance over the past year.

CEO

Raju Mohan (67 yo)

7.2yrs
Tenure
US$1,283,015
Compensation

Dr. Raju S. Mohan, Ph.D. founded Ventyx Biosciences, Inc. in November 2018 and serves as its Chief Executive Officer and Director since November 2018 and serves as its President since November 22, 2023. Dr...

Leadership Team

NamePositionTenureCompensationOwnership
Sheila Gujrathi
Executive Chairperson4.7yrsUS$335.93k0.18%
$ 1.0m
Raju Mohan
Founder7.2yrsUS$1.28m3.33%
$ 18.6m
Matthew Moore
Chief Operating Officer1.7yrsUS$1.92m0%
$ 0
Mark Forman
Chief Medical Officer1.4yrsUS$937.47k0.0084%
$ 46.9k
Roy Gonzales
Senior VP of Finance and Principal Financial & Accounting Officer1.4yrsno data0.0075%
$ 41.6k
John Nuss
Chief Scientific Officer7yrsUS$3.89m0.69%
$ 3.8m
Snehal Naik
Senior VP of Clinical Development1yrno datano data
Kathy Ogilvie
Senior VP of Translational & Nonclinical Research1yrno datano data
Arline Nakanishi
Senior Vice President of Biometrics1yrno datano data
1.4yrs
Average Tenure
58yo
Average Age

Experienced Management: VTYX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sheila Gujrathi
Executive Chairperson4.7yrsUS$335.93k0.18%
$ 1.0m
Raju Mohan
Founder7.2yrsUS$1.28m3.33%
$ 18.6m
Allison Hulme
Independent Director4yrsUS$170.83k0%
$ 0
Somasundaram Subramaniam
Independent Director7.2yrsUS$174.33k0%
$ 0
Alexa Kimball
Member of Scientific Advisory Boardno datano datano data
James Krueger
Member of Scientific Advisory Boardno datano datano data
Bruce Sands
Member of Scientific Advisory Boardno datano datano data
William White
Independent Director4.7yrsUS$172.33k0%
$ 0
Don Frail
Chairman of Scientific Advisory Board1yrno datano data
Onaiza Cadoret-Manier
Independent Director4yrsUS$173.83k0%
$ 0
Ted Dawson
Member of Scientific Advisory Board1yrno datano data
Paul Cremer
Member of Scientific Advisory Board1yrno datano data
4.0yrs
Average Tenure
61.5yo
Average Age

Experienced Board: VTYX's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 07:53
End of Day Share Price 2026/01/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ventyx Biosciences, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward NashCanaccord Genuity
Chris ShibutaniGoldman Sachs
Emily BodnarH.C. Wainwright & Co.